4.7 Review

Concise Review: Prostate Cancer Stem Cells: Current Understanding

Journal

STEM CELLS
Volume 36, Issue 10, Pages 1457-1474

Publisher

OXFORD UNIV PRESS
DOI: 10.1002/stem.2859

Keywords

Prostate; Cancer; Cancer stem cells; Heterogeneity; Metabolism

Funding

  1. Deutsche Forschungsgemeinschaft (DFG) [273676790]
  2. Wilhelm Sander-Stiftung [2017.106.1]
  3. DLR Project Management Agency [01DK17047]
  4. BMBF [03Z1NN11]
  5. U.S. National Institutes of Health (NIH) [R01-CA155693]
  6. Department of Defense [W81XWH-14-1-0575, W81XWH-16-1-0575]
  7. Chinese Ministry of Science and Technology (MOST) [2016YFA0101203]
  8. NCI center grant [P30CA016056]
  9. Austrian Science Fund (FWF) [P29457]
  10. Austrian National Bank [ONB 17620]
  11. Ingrid Shaker-Nessmann Cancer Research Foundation
  12. RPCCC
  13. Austrian Science Fund (FWF) [P29457] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

Prostate cancer (PCa) is heterogeneous, harboring phenotypically diverse cancer cell types. PCa cell heterogeneity is caused by genomic instability that leads to the clonal competition and evolution of the cancer genome and by epigenetic mechanisms that result in subclonal cellular differentiation. The process of tumor cell differentiation is initiated from a population of prostate cancer stem cells (PCSCs) that possess many phenotypic and functional properties of normal stem cells. Since the initial reports on PCSCs in 2005, there has been much effort to elucidate their biological properties, including unique metabolic characteristics. In this Review, we discuss the current methods for PCSC enrichment and analysis, the hallmarks of PCSC metabolism, and the role of PCSCs in tumor progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available